Am I eligible for 'massively underclaimed' £5,700 health benefit?
Lewis highlighted the underutilised attendance allowance earlier this week, which provides money to pensioners with disabilities.
Writing in the Money Saving Expert newsletter, Lewis said: "For many older people who are ill or start to face mental or physical disability, life doesn't just get tougher, it gets costlier too.
'That's why 18 months ago we launched our attendance allowance guide and awareness campaign, and successes have flooded in since. Yet it remains massively underclaimed.'
A recent study by Policy in Practice found more than a million pensioners could be missing out on the benefit, meaning over £5bn of unclaimed benefits.
What is attendance allowance?
Attendance allowance – also known as pension age disability payment in Scotland – is a non-means-tested weekly payment to help cover the costs of pensioners who need support with some form of disability.
It is designed for pensioners over the age of 66 with a wide range of disabilities to cover the costs of someone assisting them with their day-to-day life.
There are two rates available depending on the severity of the disability. They are:
The lower rate of £73.90 a week, equivalent to £3,842 a year. This is for people who need help either during the day or the night.
The higher rate of £110.40 a week, equivalent to £5,740 a year. This is for people who need help during the day and the night.
Crucially, you do not need to actually be receiving care to get the benefit, you only need to have one of the listed disabilities.
How do I know which benefits I'm entitled to?
There are numerous different services that can tell you if you are possibly missing out on a benefit.
You will need to fill in an extensive form that will ask you questions about your income, assets, age, disabilities and dependents.
The government has its own calculator you can view here.
Citizens Advice also runs its own system that you can fill out online, or you can contact them over the phone.
Lewis's MoneySavingExpert website also has a '10 minutes benefit calculator' that you can fill out here.
How do I claim the allowance?
One of the biggest myths around attendance allowance is who qualifies for it.
To qualify, you only need to meet the following criteria:
Be over the age of 66
Have a qualifying disability
That is it, you don't need to be claiming state pension and as long as you are not earning more than £100,000 a year, you can claim the benefit.
There is no defined list of what conditions can qualify you for claiming attendance allowance.
Illnesses like Parkinson's, dementia and blindness are almost guaranteed to get you on the benefit, but if you can argue your condition means you need someone else to help you with your day-to-day life you may qualify for it.
To claim it, you will need to prove that a doctor or some other medical professional has said you could benefit from outside help.
This help could come in the form of assistance with food preparation, getting dressed, or communicating with others.
You can also qualify if you need supervision when carrying out tasks. This is usually for people with mental disabilities who may, for example, need to be supervised when taking their medicines.
You will automatically get the higher rate if you are terminally ill and not expected to live more than a year.
To claim the allowance, you will need to fill out a long form, but someone else, like a family member or carer, can help you with it. You can find it here on the government's website.
Once sent, you may have to attend an assessment, but not everyone is required to do this.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
BofA Maintains a Sell Rating on GSK plc (GSK), Sets a PT of p1,510
GSK plc (NYSE:GSK) is one of the best . On July 15, BofA analyst Sachin Jain maintained a Sell rating on GSK plc (NYSE:GSK) and set a price target of p1,510.00. A doctor and a patient discussing a therapy plan that includes pharmaceutical products. The analyst based the rating on factors related to the company's Blenrep drug, stating that the FDA briefing documents highlighted considerable concerns regarding its ocular toxicity and dosing. Issues associated with these factors are central, and the FDA questioned if suitable dosages have been identified, given the poor tolerability seen in trials. The analyst further reasoned that the high ocular toxicity rates, including keratopathy and visual acuity changes, are especially alarming, as a majority of the patients experienced severe and recurrent ocular events. Jain also noted the limited applicability of trial results to the US markets because of the use of a comparator arm not approved in the US and low enrollment of US patients, resulting in an uncertain risk-reward balance for the drug and warranting a cautious stance. Formerly known as GlaxoSmithKline, GSK plc (NYSE:GSK) is a global healthcare and biopharmaceutical corporation that develops and distributes a range of vaccines, medications, and consumer health items. It is based in the United Kingdom and has over 20 vaccines in its portfolio, positioning it as a leader in vaccines, immunology, and respiratory therapies. The company also develops cancer treatments for multiple myeloma, ovarian cancer, and endometrial cancer in addition to other drugs. While we acknowledge the potential of GSK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
21 minutes ago
- Yahoo
Boy, 7, Nearly Dies After Swallowing Magnets from Popular Game: ‘My Worst Nightmare'
NEED TO KNOW Naomi Rivers said she found her 7-year-old son Eli choking after he swallowed magnets from the game Kluster, which is marketed to ages 14 and up Eli needed emergency surgery and was at risk for severe internal damage from the magnets snapping together inside his body Rivers is now urging others to make sure that the game is not used by young childrenA 7-year-old boy nearly died after swallowing magnets from a popular game, putting him at risk for severe internal damage. On May 11, Naomi Rivers — from Grantham, England — was in her home when she suddenly heard her son Eli cry out in distress while he was watching TV. The 35-year-old found him choking and rushed to his aid. 'He was so panicked and he was really crying, it was really, really awful. I have a fear of choking anyway — it was my worst nightmare come to life,' she told Kennedy News and Media, via the Daily Mail. Rivers said her son looked at her in "pure panic" and admitted to swallowing two magnets from a game, Kluster. 'He was putting one magnet on either side of his hand, and on different places on his body to see if they would stick together,' she said. 'Then he told me he wanted to see if they'd still stick if there was saliva between them — so he put one on the inside and one on the outside of his mouth,' she explained. 'They connected — and then he put them both in his mouth. He said he got the urge to swallow. He was choking on it because they're just smaller than a mint humbug.' Kluster is marketed as a dexterity game. Players take turns placing magnetic stones within a circle of rope, trying to avoid triggering a chain reaction of the magnets snapping together. Borderline Editions, the game's manufacturer, states that the recommended age for playing Kluster is 14 and up, which is noted on its packaging and website. The company states: 'Kluster contains small magnets with a magnetic induction flux greater than 50 kG²mm² which can be ingested. Therefore Kluster is not a toy and should be kept out of reach of children under 14 years old. Magnets stuck to each other or to a metal object inside the human body can cause serious injury or death. If magnets are swallowed or inhaled, seek medical assistance immediately.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. Eli was rushed to Grantham and District Hospital, where an X-ray revealed that the magnets snapped together inside of his stomach, traveled to his small intestine and got stuck. 'When we told the doctors he'd swallowed two magnets, a lot happened very, very quickly,' Rivers recalled. 'Because it was more than one, there was a serious risk — they said he needed immediate treatment.' is now available in the Apple App Store! Download it now for the most binge-worthy celeb content, exclusive video clips, astrology updates and more! Rivers said doctors were concerned the magnets would attract through the walls of vital organs or tissue, causing life-threatening internal damage. They tried using laxatives, performing an endoscopy and keyhole surgery to remove them but all were unsuccessful. With a high risk of internal damage, doctors transferred him to Queen's Medical Center in Nottingham for emergency surgery. 'They tried with multiple instruments and just couldn't get them,' Rivers said. 'In the end they opened him up — the incision was about 10cm, or four inches.' Following the six-hour surgery on May 22, Eli spent four days in the hospital before making a full recovery. Rivers said she has thrown the game away and is now urging other parents to make sure that it's not used by young children. 'You want to encourage children to play with toys to get them off devices — and then something like this happens,' she told the outlet. 'My recommendation would be to not have these magnet toys around at all, and to educate children on how dangerous they are.' Read the original article on People
Yahoo
2 hours ago
- Yahoo
GSK's Blenrep faces setback as FDA cancer committee votes against approval
The US Food and Drug Administration's (FDA's) Oncologic Drugs Advisory Committee (ODAC) has voted against the benefit/risk profile of GSK's Blenrep (belantamab mafodotin) just days before the drug's Prescription Drug User Fee Act (PDUFA) date. This marks a significant setback for the UK-based pharma company, which is aiming to regain approval of the therapy after it was pulled from the US market in 2022 due to concerns raised by late-stage trial data. Blenrep was approved under the FDA accelerated approval process in 2020 to treat multiple myeloma (MM). It is an antibody drug conjugate (ADC) that combines a humanised BCMA monoclonal antibody with the cytotoxic agent auristatin F, linked together by a non-cleavable linker. The ODAC committee had a 7–1 split against the combination of Blenrep plus pomalidomide and steroid dexamethasone and a 5-3 split against the combination of Blenrep with bortezomib and dexamethasone. GSK states it remains confident in the benefit/risk profile of Blenrep as a combination therapy and will continue to work closely with the FDA as they complete the review of the drug in patients with relapsed or refractory multiple myeloma (r/r MM). The FDA will consider the recommendation of the committee as it finalises its review on Blenrep in advance of the 23 July PDUFA date. The concern of ocular toxicity was first highlighted in a document published ahead of the ODAC meeting that took place on 17 July. The recommendation given by ODACs is usually followed by the FDA when deciding if a drug should be approved. Data supporting the drug's approval comes from the DREAMM-7 (NCT04246047) and DREAMM-8 (NCT04484623) studies. In the studies, many patients experienced keratopathy and Visual Acuity (KVA) events. All grade KVAs occurred in 92% and 93% of patients in DREAMM-7 and DREAMM-8, respectively, while more serious grade 3-4 events were found in 77% and 78% of patients in the same two studies. Blenrep combinations are approved in r/r MM in the UK and Japan, as well as other markets, including Switzerland, based on the results of DREAMM-8. Applications for approval in the European Union (EU) and China are ongoing, based on the results of the DREAMM-7 study. "GSK's Blenrep faces setback as FDA cancer committee votes against approval" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data